{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:46:56Z","timestamp":1790232416014,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.vaccine.2006.07.035","type":"journal-article","created":{"date-parts":[[2006,8,2]],"date-time":"2006-08-02T21:44:58Z","timestamp":1154555098000},"page":"2567-2574","source":"Crossref","is-referenced-by-count":60,"title":["Viral vectors for malaria vaccine development"],"prefix":"10.1016","volume":"25","author":[{"given":"Shengqiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bruder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise L.","family":"Doolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menzo J.E.","family":"Havenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Liljestrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Monath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Y.","family":"Naim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-chu C.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent R.","family":"Van Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Viret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Dubovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 Suppl.","key":"10.1016\/j.vaccine.2006.07.035_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.2004.71.2_suppl.0700001","article-title":"Conquering the intolerable burden of malaria: what's new, what's needed: a summary","volume":"71","author":"Breman","year":"2004","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"10.1016\/j.vaccine.2006.07.035_bib2","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.4049\/jimmunol.171.12.6961","article-title":"Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma","volume":"171","author":"Sun","year":"2003","journal-title":"J Immunol"},{"issue":"9443","key":"10.1016\/j.vaccine.2006.07.035_bib3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"issue":"9502","key":"10.1016\/j.vaccine.2006.07.035_bib4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(05)67669-6","article-title":"Duration of protection with RTS,S\/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial","volume":"366","author":"Alonso","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0166-6851(91)90167-5","article-title":"Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei","volume":"48","author":"Satchidanandam","year":"1991","journal-title":"Mol Biochem Parasitol"},{"issue":"11","key":"10.1016\/j.vaccine.2006.07.035_bib6","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","article-title":"Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria","volume":"90","author":"Li","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2006.07.035_bib7","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1128\/IAI.64.9.3833-3844.1996","article-title":"NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"64","author":"Tine","year":"1996","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.035_bib8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","author":"Ockenhouse","year":"1998","journal-title":"J Infect Dis"},{"issue":"Pt. 5","key":"10.1016\/j.vaccine.2006.07.035_bib9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.07.035_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nm0498-397","article-title":"Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara","volume":"4","author":"Schneider","year":"1998","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.035_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.vaccine.2006.07.035_bib12","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.vaccine.2006.07.035_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/427243","article-title":"Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites","volume":"191","author":"Bejon","year":"2005","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2006.07.035_bib14","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1086\/421118","article-title":"Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men","volume":"189","author":"Moorthy","year":"2004","journal-title":"J Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2006.07.035_bib15","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2006.03.029","article-title":"Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1\u20136 year old children in a malaria endemic area","volume":"24","author":"Bejon","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1073\/pnas.0307158101","article-title":"A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses","volume":"101","author":"Prieur","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4049\/jimmunol.175.1.599","article-title":"Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity","volume":"175","author":"Hutchings","year":"2005","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2006.07.035_bib18","doi-asserted-by":"crossref","first-page":"12321","DOI":"10.1128\/JVI.79.19.12321-12331.2005","article-title":"Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys","volume":"79","author":"Liang","year":"2005","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.07.035_bib19","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.4049\/jimmunol.158.3.1268","article-title":"Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria","volume":"158","author":"Rodrigues","year":"1997","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2006.07.035_bib20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0264-410X(98)00181-9","article-title":"Efficient induction of protective anti-malaria immunity by recombinant adenovirus","volume":"16","author":"Rodrigues","year":"1998","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2006.07.035_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0092-8674(03)01023-7","article-title":"Plasmodium biology: genomic gleanings","volume":"115","author":"Aravind","year":"2003","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1073\/pnas.012590199","article-title":"A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum","volume":"99","author":"Stowers","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.vaccine.2006.07.035_bib23","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/IAI.73.7.3963-3970.2005","article-title":"Posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate","volume":"73","author":"Giersing","year":"2005","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2006.07.035_bib24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/glycob\/9.12.1347","article-title":"Glycosylation and proteolytic processing of70 kDa C-terminal recombinant polypeptides of Plasmodium falciparum merozoite surface protein 1 expressed in mammalian cells","volume":"9","author":"Yang","year":"1999","journal-title":"Glycobiology"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2006.07.035_bib25","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/j.vaccine.2004.03.050","article-title":"Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif","volume":"22","author":"Bruna-Romero","year":"2004","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2006.07.035_bib26","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1128\/JVI.77.16.8729-8735.2003","article-title":"Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines","volume":"77","author":"Barouch","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2006.07.035_bib28","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.035_bib30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/00002030-200405210-00019","article-title":"Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector","volume":"18","author":"Kostense","year":"2004","journal-title":"Aids"},{"issue":"15","key":"10.1016\/j.vaccine.2006.07.035_bib31","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2006.07.035_bib32","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1128\/JVI.79.15.9694-9701.2005","article-title":"Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity","volume":"79","author":"Lemckert","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0042-6822(03)00161-2","article-title":"Development of adenovirus serotype 35 as a gene transfer vector","volume":"311","author":"Seshidhar Reddy","year":"2003","journal-title":"Virology"},{"issue":"23","key":"10.1016\/j.vaccine.2006.07.035_bib34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/sj.gt.3302097","article-title":"Human adenovirus type 35: nucleotide sequence and vector development","volume":"10","author":"Gao","year":"2003","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2006.07.035_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1525-0016(03)00243-0","article-title":"Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector","volume":"8","author":"Sakurai","year":"2003","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/IAI.74.1.313-320.2006","article-title":"Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice","volume":"74","author":"Ophorst","year":"2006","journal-title":"Infect Immun"},{"issue":"22","key":"10.1016\/j.vaccine.2006.07.035_bib37","doi-asserted-by":"crossref","first-page":"14161","DOI":"10.1128\/JVI.79.22.14161-14168.2005","article-title":"Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys","volume":"79","author":"Nanda","year":"2005","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.035_bib38","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02762410","article-title":"Manipulation of the Semliki Forest virus genome and its potential for vaccine construction","volume":"5","author":"Atkins","year":"1996","journal-title":"Mol Biotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0378-1119(96)00679-8","article-title":"Alphavirus expression vectors and their use as recombinant vaccines: a minireview","volume":"190","author":"Tubulekas","year":"1997","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.035_bib41","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1073\/pnas.96.8.4598","article-title":"Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors","volume":"96","author":"Polo","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.035_bib43","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1128\/JVI.72.8.6907-6910.1998","article-title":"Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice","volume":"72","author":"Tsuji","year":"1998","journal-title":"J Virol"},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2006.07.035_bib44","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.vaccine.2004.02.015","article-title":"Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes","volume":"22","author":"Chen","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.virol.2005.07.017","article-title":"Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles","volume":"341","author":"Sundback","year":"2005","journal-title":"Virology"},{"issue":"Pt. 2","key":"10.1016\/j.vaccine.2006.07.035_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1099\/vir.0.80481-0","article-title":"Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1","volume":"86","author":"Nordstrom","year":"2005","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.07.035_bib47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni889","article-title":"Lineage relationship and protective immunity of memory CD8 T cell subsets","volume":"4","author":"Wherry","year":"2003","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.07.035_bib48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20042463","article-title":"IL-4 receptor expression on CD8+ T cells is required for the development of protective memory responses against liver stages of malaria parasites","volume":"202","author":"Morrot","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2006.07.035_bib49","unstructured":"International Travel and Health: Vaccination Requirements and Health Advice. World Health Organization, Geneva, 1996."},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.035_bib50","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.035_bib51","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2006.07.035_bib52","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4269\/ajtmh.2005.72.74","article-title":"Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells","volume":"72","author":"Brandler","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.07.035_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0065-3527(03)61013-4","article-title":"Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis","volume":"61","author":"Lai","year":"2003","journal-title":"Adv Virus Res"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20041526","article-title":"Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model","volume":"201","author":"Tao","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2006.07.035_bib56","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1006\/jmbi.2001.5258","article-title":"Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus","volume":"315","author":"Bonaldo","year":"2002","journal-title":"J Mol Biol"},{"issue":"23","key":"10.1016\/j.vaccine.2006.07.035_bib57","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.vaccine.2006.07.035_bib58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","article-title":"A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV","volume":"78","author":"Lorin","year":"2004","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2006.07.035_bib59","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","article-title":"A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice","volume":"73","author":"Singh","year":"1999","journal-title":"J Virol"},{"issue":"17\u201319","key":"10.1016\/j.vaccine.2006.07.035_bib60","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0264-410X(00)00523-5","article-title":"Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses","volume":"19","author":"Wang","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1086\/426824","article-title":"Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis","volume":"191","author":"Despres","year":"2005","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2006.07.035_bib62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nm0898-945","article-title":"T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses","volume":"4","author":"Fehr","year":"1998","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2006.07.035_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/vim.2005.18.317","article-title":"Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector","volume":"18","author":"Tangy","year":"2005","journal-title":"Viral Immunol"},{"issue":"9206","key":"10.1016\/j.vaccine.2006.07.035_bib64","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(99)95140-1","article-title":"Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial","volume":"355","author":"Dilraj","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2006.07.035_bib65","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2005.08.045","article-title":"Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children","volume":"24","author":"Wong-Chew","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2006.07.035_bib66","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06009054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06009054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:28:22Z","timestamp":1683545302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06009054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":66,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0264410X06009054"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.07.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}